• Je něco špatně v tomto záznamu ?

Prenylated phenolics from Morus alba against MRSA infections as a strategy for wound healing

G. Škovranová, M. Čulenová, J. Treml, L. Dzurická, I. Marova, A. Sychrová

. 2022 ; 13 (-) : 1068371. [pub] 20221130

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031171

Antimicrobial resistance is a public health threat and the increasing number of multidrug-resistant bacteria is a major concern worldwide. Common antibiotics are becoming ineffective for skin infections and wounds, making the search for new therapeutic options increasingly urgent. The present study aimed to investigate the antibacterial potential of prenylated phenolics in wound healing. Phenolic compounds isolated from the root bark of Morus alba L. were investigated for their antistaphylococcal potential both alone and in combination with commonly used antibiotics. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) were determined by microdilution and agar method. Synergy was investigated using the checkerboard titration technique. Membrane-disrupting activity and efflux pump inhibition were evaluated to describe the potentiating effect. Prenylated phenolics inhibited bacterial growth of methicillin-resistant Staphylococcus aureus (MRSA) at lower concentrations (MIC 2-8 μg/ml) than commonly used antibiotics. The combination of active phenolics with kanamycin, oxacillin, and ciprofloxacin resulted in a decrease in the MIC of the antimicrobial agent. Kuwanon C, E, T, morusin, and albafuran C showed synergy (FICi 0.375-0.5) with oxacillin and/or kanamycin. Prenylated phenolics disrupted membrane permeability statistically significantly (from 28 ± 16.48% up to 73 ± 2.83%), and membrane disruption contributes to the complex antibacterial activity against MRSA. In addition, kuwanon C could be considered an efflux pump inhibitor. Despite the antibacterial effect on MRSA and the multiple biological activities, the prenylated phenolics at microbially significant concentrations have a minor effect on human keratinocyte (HaCaT) viability. In conclusion, prenylated phenolics in combination with commonly used antibiotics are promising candidates for the treatment of MRSA infections and wound healing, although further studies are needed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031171
003      
CZ-PrNML
005      
20230127131053.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2022.1068371 $2 doi
035    __
$a (PubMed)36532741
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Škovranová, Gabriela $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czechia
245    10
$a Prenylated phenolics from Morus alba against MRSA infections as a strategy for wound healing / $c G. Škovranová, M. Čulenová, J. Treml, L. Dzurická, I. Marova, A. Sychrová
520    9_
$a Antimicrobial resistance is a public health threat and the increasing number of multidrug-resistant bacteria is a major concern worldwide. Common antibiotics are becoming ineffective for skin infections and wounds, making the search for new therapeutic options increasingly urgent. The present study aimed to investigate the antibacterial potential of prenylated phenolics in wound healing. Phenolic compounds isolated from the root bark of Morus alba L. were investigated for their antistaphylococcal potential both alone and in combination with commonly used antibiotics. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) were determined by microdilution and agar method. Synergy was investigated using the checkerboard titration technique. Membrane-disrupting activity and efflux pump inhibition were evaluated to describe the potentiating effect. Prenylated phenolics inhibited bacterial growth of methicillin-resistant Staphylococcus aureus (MRSA) at lower concentrations (MIC 2-8 μg/ml) than commonly used antibiotics. The combination of active phenolics with kanamycin, oxacillin, and ciprofloxacin resulted in a decrease in the MIC of the antimicrobial agent. Kuwanon C, E, T, morusin, and albafuran C showed synergy (FICi 0.375-0.5) with oxacillin and/or kanamycin. Prenylated phenolics disrupted membrane permeability statistically significantly (from 28 ± 16.48% up to 73 ± 2.83%), and membrane disruption contributes to the complex antibacterial activity against MRSA. In addition, kuwanon C could be considered an efflux pump inhibitor. Despite the antibacterial effect on MRSA and the multiple biological activities, the prenylated phenolics at microbially significant concentrations have a minor effect on human keratinocyte (HaCaT) viability. In conclusion, prenylated phenolics in combination with commonly used antibiotics are promising candidates for the treatment of MRSA infections and wound healing, although further studies are needed.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čulenová, Marie $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia
700    1_
$a Treml, Jakub $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czechia
700    1_
$a Dzurická, Lucia $u Institute of Food Science and Biotechnology, Faculty of Chemistry, Brno University of Technology, Brno, Czechia
700    1_
$a Marova, Ivana $u Institute of Food Science and Biotechnology, Faculty of Chemistry, Brno University of Technology, Brno, Czechia
700    1_
$a Sychrová, Alice $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 1068371
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36532741 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131044 $b ABA008
999    __
$a ok $b bmc $g 1889397 $s 1182504
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 13 $c - $d 1068371 $e 20221130 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace